Eye on 2025: Viridian Sets Priorities After Positive Phase 3 TED Data Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company committed to developing potential best-in-class treatments for serious and rare…
Cancer Treatment Localization: Boston Oncology Arabia & SPIMACO Partner in Saudi Arabia In a groundbreaking move to enhance cancer care in the Middle East, Boston Oncology Arabia and SPIMACO have…
Viz.ai Partners with 3 Pharma Companies, Expands to 60,000 Providers Viz.ai, a leader in AI-powered disease detection and care coordination, has announced major achievements in its mission to revolutionize healthcare…
Stoke Therapeutics Announces Phase 3 Study Plans for Zorevunersen in Dravet Syndrome Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company focused on RNA medicine to restore protein expression, announced today…
Announces REZZAYO® Approval in Spain for Invasive Candidiasis Treatment by Mundipharma Mundipharma announces today that Spain’s Ministry of Health has approved reimbursement for REZZAYO® (rezafungin acetate) as a treatment for…
Arcturus Begins Phase 2 Dosing for CF and OTC Deficiency Arcturus Therapeutics Holdings Inc., a pioneering company in mRNA medicine, announced that it has initiated Phase 2 multiple ascending dose…
FDA Grants Fast Track to Star Therapeutics for VGA039 in VWD Star Therapeutics, a clinical-stage biotechnology company focused on developing cutting-edge antibodies, has announced that the U.S. Food and Drug…
Appoints Giancarlo Benelli as Head of Europe at BeiGene BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company set to rebrand as BeOne Medicines Ltd., appoints Giancarlo…
Gene Therapy: JCR Pharmaceuticals and Modalis Advance Research JCR Pharmaceuticals Co., Ltd. (TOKYO:4552) and Modalis Therapeutics Corporation (TOKYO:4883) have announced a major advancement in their joint research program aimed at…
Therapies: PharmaEssentia Ensures Reliable Interferon Access PharmaEssentia (TWSE: 6446), a leading global biopharmaceutical company, has reaffirmed its commitment to ensuring robust and reliable access to critical interferon therapies, particularly in…
OS Therapies Completes $6 Million Private Placement OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company specializing in cancer immunotherapy and antibody-drug conjugates, today announced the successful completion of a…
Verastem Unveils Critical FDA Review of Avutometinib-Defactinib for Ovarian Cancer Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new cancer treatments, has announced that the U.S. Food and…